The incidence of pneumococci resistant to penicillin G and other ␤-lactam and non-␤-lactam compounds has increased at an alarming rate (1). The problem is exacerbated by the tendency of these organisms to spread from country to country and from continent to continent (14, 15) . In the United States a recent survey has shown an increase in penicillin resistance from Ͻ5% before 1989 (Ͻ0.02% of isolates for which MICs are Ն2.0 g/ml) to 6.6% in 1991 to 1992 (1.3% of isolates for which MICs are Ն2.0 g/ml) (3). In another recent survey, 23.6% of pneumococci were not susceptible to penicillin (5). High rates of isolation of penicillin-intermediate and -resistant pneumococci occur in middle ear fluids from patients with refractory otitis media (2).
The incidence of pneumococci resistant to penicillin G and other ␤-lactam and non-␤-lactam compounds has increased at an alarming rate (1) . The problem is exacerbated by the tendency of these organisms to spread from country to country and from continent to continent (14, 15) . In the United States a recent survey has shown an increase in penicillin resistance from Ͻ5% before 1989 (Ͻ0.02% of isolates for which MICs are Ն2.0 g/ml) to 6.6% in 1991 to 1992 (1.3% of isolates for which MICs are Ն2.0 g/ml) (3). In another recent survey, 23 .6% of pneumococci were not susceptible to penicillin (5) . High rates of isolation of penicillin-intermediate and -resistant pneumococci occur in middle ear fluids from patients with refractory otitis media (2) .
There is a need of oral compounds for treatment of otitis media, sinusitis, bronchitis, and community-acquired pneumonia caused by penicillin-intermediate and -resistant pneumococci (7, 8, 11, 12) . Quinolones such as ciprofloxacin and ofloxacin yield moderate in vitro activities against pneumococci (11, 12, 17, 18, 21, 22) .
BAY 12-8039 is a new experimental broad-spectrum 8-methoxyquinolone with activities against gram-positive and -negative aerobes, anaerobes, chlamydiae, Mycoplasma spp., and Legionella spp. (4, 6, 9, 10, 13, 25) . This study employs standard agar dilution MIC methodology to test the activities of BAY 12-8039, ciprofloxacin, ofloxacin, sparfloxacin, ampicillin, amoxicillin, cefuroxime, and cefpodoxime against 205 penicillin-susceptible and -resistant pneumococci. Additionally, the activities of these compounds against 12 penicillin-susceptible and -resistant pneumococci were investigated by broth dilution (MIC) and time-kill analyses.
To obtain MICs by agar dilution, we used 53 penicillinsusceptible (MICs, Յ0.06 g/ml), 76 penicillin-intermediate (MICs, 0.125 to 1.0 g/ml), and 76 penicillin-resistant (MICs, 2.0 to 16.0 g/ml) pneumococcal strains. For time-kill studies, four penicillin-susceptible, four penicillin-intermediate, and four penicillin-resistant strains were tested. Agar dilution was performed as described previously (11) . Broth dilutions to obtain MICs for 12 strains were performed according to National Committee for Clinical Laboratory Standards recommendations (16) . Standard quality-control strains were included in each run of agar and broth dilutions (16) .
For time-kill testing, tubes containing 5 ml of cation-adjusted Mueller-Hinton broth plus 5% lysed horse blood with doubling antibiotic concentrations were inoculated with 5 ϫ 10 5 to 5 ϫ 10 6 CFU/ml and incubated at 35°C in a shaking water bath (17, 20) . Tubes were vortexed, and the contents were plated for viability counts. The original inoculum was determined by using the untreated growth control (17, 20) . Viability counts of antibiotic-containing suspensions were performed at 0, 3, 6, 12, and 24 h, by plating dilutions onto 5% sheep blood agar plates. The lower limit of sensitivity of colony counts was 300 CFU/ml (17, 20) .
Time-kill results were analyzed by determining the number of strains which yielded a change in log 10 CFU per milliliter of Ϫ1, Ϫ2, or Ϫ3 at 0, 3, 6, 12, and 24 h, compared to counts at time zero. Antimicrobials were considered bactericidal at the lowest concentration that reduced the original inoculum by Ն3 log 10 CFU/ml (99.9%) at each of the time periods, and they were considered bacteriostatic if the inoculum was reduced by 0 to 3 log 10 CFU/ml. With the sensitivity threshold and inocula used in these studies, no problems were encountered in delineating 99.9% killing, when this was present. Bacterial carryover was addressed as described previously (20) .
Results of MIC testing are presented in Table 1 . MICs of quinolones were independent of those of penicillin G. BAY 12-8039 yielded the lowest MICs of the quinolones tested (its MICs at which 50 and 90% of isolates are inhibited [MIC 50 and MIC 90 , respectively] were 0.125 and 0.25 g/ml), with all strains being inhibited by 0.5 g/ml. Sparfloxacin was the nextmost-active quinolone, with a MIC 50 and a MIC 90 of 0.25 and 0.5 g/ml, respectively, followed by ciprofloxacin and ofloxacin (both of which had a MIC 50 MICs obtained by broth dilution for the 12 strains studied by time-kill analysis are listed in Table 2 . MICs of individual strains were within one dilution of those obtained by agar dilution. Time-kill analysis (Table 3) showed that, at two times the MIC after 24 h, BAY 12-8039, ciprofloxacin, ampicillin, and cefuroxime were bactericidal (99.9% killing) against all strains; other compounds were bactericidal at four times the MIC. After 12 h, BAY 12-8039 showed 90% killing of all strains at the MIC and 99% killing at two times the MIC; after 6 h, it showed 99% killing of all strains at two times the MIC; and after 3 h, it showed 90% killing of all strains at two times the MIC. Similar results relative to the MICs were obtained for ciprofloxacin, ofloxacin, and sparfloxacin. After 12 h, amoxicillin showed 90% killing of all strains at two times the MIC and 99% killing at four times the MIC; after 6 h, it showed 90% killing of all strains at four times the MIC; and after 3 h, it showed 90% killing of all strains at eight times the MIC. Kill patterns of all ␤-lactams were similar, relative to their respective MICs. However, quinolones killed strains slightly more rapidly than ␤-lactams after 3 and 6 h.
BAY 12-8039 is a new broad-spectrum methoxyquinolone (4, 6, 9, 10, 13, 25) . Other fluoroquinolones with expanded gram-positive coverage which are currently being developed or are in use are levofloxacin, sparfloxacin, grepafloxacin, gatifloxacin, clinafloxacin, trovafloxacin, and DU-6859a (12, 17, 18, (20) (21) (22) (23) (24) . MICs of levofloxacin range between 0.5 and 2 g/ml, while those of grepafloxacin, sparfloxacin, and gatifloxacin are similar (0.125 to 0.5 g/ml) for these strains (18, (21) (22) (23) . MICs of clinafloxacin and DU-6859a are a few dilutions lower than those of the last two compounds (18, 24) . MICs of trovafloxacin are similar to those of BAY 12-8039 (18) . The superior antipneumococcal activity of amoxicillin compared to those of other oral ␤-lactam agents has been described before (19) .
MIC and time-kill data of BAY 12-8039 for pneumococci are similar to those published previously from studies of smaller numbers of strains (4, 25) . With an oral dosage regimen of 400 mg daily, a maximum concentration of the drug in serum of 3.2 g/ml has been obtained in humans; the time to maximum concentration of the agent in serum is 1 to 2 h, and its half-life is approximately 12 h (13).
Dalhoff et al. have shown BAY 12-8039 to have concentration-dependent killing throughout all concentrations studied, whereas the bactericidal effects of ciprofloxacin, ofloxacin, and sparfloxacin were concentration dependent only up to 0.25 to 1 times the MIC. Although MICs of BAY 12-8039 and sparfloxacin differed by a factor of 2, killing rates were qualitatively and quantitatively different. Resistance to BAY 12-8039 developed less frequently than resistance to ciprofloxacin in pneumococci (4). Protein binding of BAY 12-8039 (Ͻ50%) is similar to that of many quinolones but less than that of trovafloxacin (85%) (25) .
The results of our study indicate good in vitro antipneumococcal activity of BAY 12-8039, with MICs well within achievable levels in serum. If no significant toxicologic results are found, and pending favorable results of pharmacokinetic and in vivo efficacy studies, this compound will be a promising agent for outpatient treatment of pneumococcal respiratory tract infections in areas with a high incidence of penicillinresistant strains. Ϫ1  Ϫ2  Ϫ3  Ϫ1  Ϫ2  Ϫ3  Ϫ1  Ϫ2  Ϫ3  Ϫ1  Ϫ2  Ϫ3 
